{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T10:14:36Z","timestamp":1720779276176},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1684\/bdc.2012.1562","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T15:58:43Z","timestamp":1565711923000},"page":"S37-S45","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S","title":["Strat\u00e9gie de prise en charge des cancers de la prostate r\u00e9fractaires \u00e0 la castration"],"prefix":"10.1016","volume":"99","author":[{"given":"Marine","family":"Gross-Goupil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Roca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Pasticier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Ravaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2012.1562_bib0005","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2005.01.529","article-title":"Natural history of rising serum prostate specific antigen in men with castrate nonmetastatic prostate cancer","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1562_bib0010","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2012.1562_bib0015","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2012.1562_bib0020","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate. Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1562_bib0025","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2011.01.025","article-title":"EAU guidelines on prostate cancer. PartII: treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"59","author":"Mottet","year":"2011","journal-title":"Eur Urol"},{"key":"10.1684\/bdc.2012.1562_bib0030","unstructured":"NCCN Clinical Practice Guidelines in Oncology; http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"key":"10.1684\/bdc.2012.1562_bib0035","doi-asserted-by":"crossref","first-page":"v129","DOI":"10.1093\/annonc\/mdq174","article-title":"ESMO Guidelines Working Group. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Horwich","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2012.1562_bib0040","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1200\/JCO.1997.15.8.2928","article-title":"Bicalutamide for advanced prostate cancer: the natural versus treated history of disease","volume":"15","author":"Scher","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1562_bib0045","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1464-410X.2005.05714.x","article-title":"Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer","volume":"96","author":"Nakabayashi","year":"2005","journal-title":"BJU Int"},{"key":"10.1684\/bdc.2012.1562_bib0050","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/cncr.23473","article-title":"Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group Trial (SWOG9426)","volume":"112","author":"Sartor","year":"2008","journal-title":"Cancer"},{"key":"10.1684\/bdc.2012.1562_bib0055","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3816\/CGC.2002.n.009","article-title":"The evolving role of estrogen therapy in prostate cancer","volume":"1","author":"Oh","year":"2002","journal-title":"Clin Prostate Cancer"},{"key":"10.1684\/bdc.2012.1562_bib0060","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000087797","article-title":"Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial","volume":"75","author":"Manikandan","year":"2005","journal-title":"Urol Int"},{"key":"10.1684\/bdc.2012.1562_bib0065","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/annonc\/mdp112","article-title":"Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration resistant prostate cancer","volume":"20","author":"Serrate","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2012.1562_bib0070","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.coph.2008.06.004","article-title":"Targeting CYP17: established and novel approaches in prostate cancer","volume":"8","author":"Yap","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"10.1684\/bdc.2012.1562_bib0075","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1200\/JCO.2004.06.037","article-title":"Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phaseIII trial (CALGB9583)","volume":"22","author":"Small","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1562_bib0080","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.5046","article-title":"PhaseII multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone","volume":"27","author":"Ryan","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1562_bib0085","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/j.1464-410X.2011.10201.x","article-title":"The use of estramustine phosphate in the modern management of advanced prostate cancer","volume":"108","author":"Ravery","year":"2011","journal-title":"BJU Int"},{"key":"10.1684\/bdc.2012.1562_bib0090","first-page":"2897","article-title":"High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer","volume":"24","author":"Fizazi","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1684\/bdc.2012.1562_bib0095","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S1470-2045(07)70284-X","article-title":"Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data","volume":"8","author":"Fizazi","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1684\/bdc.2012.1562_bib0100","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/annonc\/mdn062","article-title":"The postchemotherapy PSA surge syndrome","volume":"19","author":"Thuret","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2012.1562_bib0105","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1097\/01.ju.0000157569.59229.72","article-title":"Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer","volume":"173","author":"D\u2019Amico","year":"2005","journal-title":"J Urol"},{"key":"10.1684\/bdc.2012.1562_bib0110","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phaseIII trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1562_bib0115","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/cncr.24429","article-title":"Integrated data from 2randomized, double-blind, placebo-controlled, phase3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer","volume":"115","author":"Higano","year":"2009","journal-title":"Cancer"},{"key":"10.1684\/bdc.2012.1562_bib0120","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2012.1562_bib0125","unstructured":"http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm210174.htm"},{"key":"10.1684\/bdc.2012.1562_bib0130","series-title":"Prostate cancer: evolution or revolution?","author":"Small","year":"2011"},{"key":"10.1684\/bdc.2012.1562_bib0135","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/j.1464-410X.2010.09296.x","article-title":"Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study","volume":"106","author":"Eymard","year":"2010","journal-title":"BJU Int"},{"key":"10.1684\/bdc.2012.1562_bib0140","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.ejca.2010.04.010","article-title":"The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer","volume":"46","author":"Loriot","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1684\/bdc.2012.1562_bib0145","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1464-410X.2010.09498.x","article-title":"PhaseII study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer","volume":"107","author":"Di Lorenzo","year":"2011","journal-title":"BJU Int"},{"key":"10.1684\/bdc.2012.1562_bib0150","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1021\/jm00013a022","article-title":"Novel steroidal inhibitors of human cytochrome P45017alpha (17-alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer","volume":"38","author":"Potter","year":"1995","journal-title":"J Med Chem"},{"key":"10.1684\/bdc.2012.1562_bib0155","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2009.24.6819","article-title":"Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17inhibitor abiraterone acetate","volume":"28","author":"Reid","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1562_bib0160","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","article-title":"PhaseI clinical trial of the CYP17inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy","volume":"28","author":"Ryan","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1562_bib0165","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2012.1562_bib0170","first-page":"303","article-title":"In vitro activity of TXD258in chemotherapeutic resistant tumor cell lines","volume":"41","author":"Aller","year":"2000","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1684\/bdc.2012.1562_bib0175","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1684\/bdc.2012.1562_bib0180","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatichormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1562_bib0185","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1200\/JCO.1999.17.8.2506","article-title":"Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: results of the cancer and leukaemia group B 9182study","volume":"17","author":"Kantoff","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1562_bib0190","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/cncr.22811","article-title":"Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase2 study of ixabepilone or mitoxantrone and prednisone","volume":"110","author":"Rosenberg","year":"2007","journal-title":"Cancer"},{"key":"10.1684\/bdc.2012.1562_bib0195","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/cncr.21695","article-title":"First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?","volume":"106","author":"Michels","year":"2006","journal-title":"Cancer"},{"key":"10.1684\/bdc.2012.1562_bib0200","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/annonc\/mdn288","article-title":"TAX327 Investigators Survival and PSA response of patients in the TAX327 study who crossed over to receive docetaxel after mitoxantrone or vice versa","volume":"19","author":"Berthold","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2012.1562_bib0205","series-title":"Chimioth\u00e9rapies cytotoxiques et cancer de la prostate: standards et perspectives Bull Cancer","author":"Hadjarab","year":"2011"},{"key":"10.1684\/bdc.2012.1562_bib0210","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1684\/bdc.2012.1562_bib0215","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115302988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115302988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T04:27:56Z","timestamp":1602476876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115302988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0007455115302988"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2012.1562","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}